Interview with:
Interview by:
Produced by:
5 Jun 2018
Breakfast Brief with Prof. Dr. Olivier Michielin
In this Breakfast Brief, Prof. Dr. Olivier Michielin, Central Univercity Hospital (CHUV) in Lausanne, presents the highlights of day 4 of ASCO Congress 2018.
The following abstracts are discussed:
Source: ASCO Annual Meeting 2018
- Abstract 9502:
Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).
https://meetinglibrary.asco.org/record/159076/abstract
4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.
Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma.